Fredag 28 Augusti | 15:56:03 Europe / Stockholm
Est. tid*
2027-02-24 08:30 Bokslutskommuniké 2026
2026-11-02 18:15 Kvartalsrapport 2026-Q3
2026-08-26 - Extra Bolagsstämma 2026
2026-08-14 - Kvartalsrapport 2026-Q2
2026-05-31 - Kvartalsrapport 2026-Q1
2026-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2026-05-26 - Årsstämma
2026-03-27 - Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Koncernen omfattar tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ)

2026-08-26 14:24:00

Magle Chemoswed Holding AB (publ), org. no. 556913-4710 (the "Company"), held today, on 26 August 2026, an extraordinary general meeting (the "EGM") at the Company's premises at Agneslundsvägen 20B in Malmö, Sweden. The following resolutions were adopted at the EGM.

Resolution to amend the articles of association

The EGM resolved, in accordance with the board of directors' proposal, to amend Section 4 of the articles of association, entailing that the share capital shall amount to not less than SEK 7,000,000 and not more than SEK 28,000,000 and that the number of shares in the Company shall be not less than 140,000,000 and not more than 560,000,000.

Resolution to approve the board of directors' resolution on a directed share issue

The EGM resolved, in accordance with the board of directors' proposal, to approve the board of directors' resolution from 10 July 2026 on a share issue of a maximum of 31,980,350 shares, entailing a maximum increase of the share capital of SEK 1,599,017.50. The right to subscribe for shares shall, with deviation from the shareholders' preferential rights, only vest with PRS1 ApS and MB Holding Køge ApS. The subscription price is SEK 1.00 per share. Subscription and payment shall be made no later than on 30 September 2026.

Resolution to approve the board of directors' resolution on a directed share issue

The EGM resolved, in accordance with the board of directors' proposal, to approve the board of directors' resolution from 10 July 2026 on a share issue of a maximum of 7,500,000 shares, entailing a maximum increase of the share capital of SEK 375,000. The right to subscribe for shares shall, with deviation from the shareholders' preferential rights, only vest with PRS1 ApS. The subscription price is SEK 1.00 per share. Subscription and payment shall be made no later than on 30 September 2026.

Resolution to authorise the board of directors to resolve on issues of shares, warrants and/or convertible debentures

The EGM resolved, in accordance with the board of directors' proposal, to authorise the board of directors to, on one or several occasions during the period up until the next annual general meeting, resolve to increase the Company's share capital through the issuance of shares, warrants and/or convertible debentures, with or without deviation from the shareholders' pre-emptive rights and/or with or without provisions concerning payment in kind, set-off, or other provisions. The number of shares that may be issued pursuant to the authorisation shall not be limited in any other way than what follows from the limits of the number of shares and the share capital set out in the articles of association in force from time to time. Issuances in accordance with the authorisation shall only be made in order to fulfil the Company's obligations pursuant to the agreed terms and conditions of the restructuring.

Resolution on a directed share issue to subscribers covered by Chapter 16 of the Swedish Companies Act

The EGM resolved, in accordance with the proposal of the shareholder PRS1 ApS, on a share issue of a maximum of 11,350,000 shares, entailing a maximum increase of the share capital of SEK 567,500. The right to subscribe for shares shall, with deviation from the shareholders' preferential rights, only vest with chairman of the board Stig Løkke Pedersen (a maximum of 3,750,000 shares), board member Søren Skjold Mogensen (a maximum of 500,000 shares), previous board member Mats Pettersson (a maximum of 6,750,000 shares), and previous board member Sven-Christer Nilsson (a maximum of 350,000 shares), each privately and/or through a company. The subscription price is SEK 1.00 per share. Subscription and payment shall be made no later than on 30 September 2026.

Resolution on delisting

The EGM resolved, in accordance with the board of directors' proposal, to apply for delisting of the Company's shares from Nasdaq First North Growth Market. In accordance with the resolution, the board of directors will submit the delisting application to Nasdaq Stockholm. The application may be submitted no earlier than three months after 27 July 2026, when the market was informed of the delisting plans, i.e., no earlier than on 28 October 2026. The board of directors intends to submit the application on that same day. The last day of trading in the Company's shares on Nasdaq First North Growth Market is expected to be approximately two weeks after Nasdaq Stockholm has resolved on the delisting.

For more detailed information regarding the content and background of the resolutions, reference is made to the notice of the EGM, which has previously been published and is available on the Company's website, https://maglegroup.com.